Want to see IN:GRANULES full AI Analyst Report?
GRANULES Stock Chart & Stats
₹833.65
₹9.25(1.11%)
At close: 4:00 PM EDT
₹833.65
₹9.25(1.11%)
Day’s Range― - ―
52-Week Range₹433.00 - ₹910.00
Previous CloseN/A
Volume917.48K
Average Volume (3M)56.05K
Market Cap
₹204.20B
Enterprise Value₹157.75K
Total Cash (Recent Filing)₹6.26B
Total Debt (Recent Filing)₹18.07B
Price to Earnings (P/E)30.5
Beta0.81
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)21.14
Shares Outstanding247,796,920
10 Day Avg. Volume60,875
30 Day Avg. Volume56,048
Financial Highlights & Ratios
PEG Ratio1.39
Price to Book (P/B)2.97
Price to Sales (P/S)2.81
P/FCF Ratio125.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.03
Revenue Forecast (FY)₹62.31B
Bulls Say, Bears Say
Bulls Say
Vertical Integration Across API→PFI→FDFGranules' integrated manufacturing from APIs to finished dosage forms creates durable cost and supply advantages versus pure-play formulators. Owning upstream inputs supports margin capture, reduces reliance on external suppliers, and underpins long-term contract durability in regulated markets.
Return To Revenue Growth (FY2026 +10.9%)Resumption of revenue growth after a stagnant period signals underlying demand resilience and potentially improved utilization of manufacturing capacity. Sustained top-line growth supports fixed-cost leverage, enabling steadier EBITDA generation and investment capacity over the medium term.
Manageable Leverage And Stronger Balance SheetA conservative debt-to-equity ratio for a manufacturing business limits refinancing and liquidity risk. Combined with steady asset and equity growth, the balance sheet positions the company to fund capex, weather cyclical headwinds, and pursue strategic investments without excessive leverage strain.
Bears Say
Gross Profit Decline Despite Higher RevenueA fall in gross profit while revenue rises indicates rising input or manufacturing costs or weakened pricing power. Persistent margin compression reduces operating leverage benefits, constrains free cash flow and reinvestment capacity, and could erode competitiveness if cost trends persist.
Inconsistent Cash Conversion And FCF VolatilityVolatile free cash flow relative to earnings signals working-capital swings or varying capex needs, weakening predictability of internally generated funding. That instability can limit the firm's ability to consistently pay down debt, invest in growth, or return capital to shareholders over the medium term.
Declining Return On EquityA falling ROE implies new invested capital is yielding lower returns than in past cycles, potentially from margin pressure, competitive pricing, or slower growth. Persistently lower ROE can reduce capital allocation efficiency and limit long-term shareholder value creation.
Granules India Limited News
GRANULES FAQ
What was Granules India Limited’s price range in the past 12 months?
Granules India Limited lowest stock price was ₹433.00 and its highest was ₹910.00 in the past 12 months.
What is Granules India Limited’s market cap?
Granules India Limited’s market cap is ₹204.20B.
When is Granules India Limited’s upcoming earnings report date?
Granules India Limited’s upcoming earnings report date is Nov 05, 2026 which is in 93 days.
How were Granules India Limited’s earnings last quarter?
Granules India Limited released its earnings results on Jul 21, 2026. The company reported ₹6.95 earnings per share for the quarter, missing the consensus estimate of ₹7.7 by -₹0.75.
Is Granules India Limited overvalued?
According to Wall Street analysts Granules India Limited’s price is currently Overvalued.
Does Granules India Limited pay dividends?
Granules India Limited pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.21%. See more information on Granules India Limited dividends here
What is Granules India Limited’s EPS estimate?
Granules India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Granules India Limited have?
Granules India Limited has 247,796,920 shares outstanding.
What happened to Granules India Limited’s price movement after its last earnings report?
Granules India Limited reported an EPS of ₹6.95 in its last earnings report, missing expectations of ₹7.7. Following the earnings report the stock price went down -0.057%.
Which hedge fund is a major shareholder of Granules India Limited?
Currently, no hedge funds are holding shares in IN:GRANULES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Granules India Limited
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
Technical Analysis
Aurobindo Pharma Ltd
―
Glenmark Life Sciences Limited
―
Jubilant Pharmova Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―